Auszug
Mit Ausnahme der Hodentumoren stellen urologische Malignome typische Erkrankungen des höheren Lebensalters dar. Das Spektrum dieser malignen Erkrankungen reicht dabei von sehr langsamen Verläufen ohne klinisch relevante Auswirkungen auf Morbidität oder Mortalität bis zu aggressiven Erkrankungen mit erheblichen Konsequenzen. In der Behandlung älterer Patienten gilt es, die Konsequenzen einer Therapie gegen den natürlichen Verlauf der Erkrankung unter Berücksichtigung der individuellen Belastbarkeit und Prognose sowie der Patientenpräferenzen abzuwägen. Wesentliche Fragen, die es vor einer Therapieentscheidung zu beantworten gilt, sind:
-
- Ist die Tumorerkrankung für den Patienten in Bezug auf die Lebenserwartung limitierend?
-
- Ist die Tumorerkrankung in Bezug auf die Lebensqualität des Patienten limitierend?
-
- Verbessert die Therapie die Lebensqualität oder Lebenserwartung?
-
- Stehen die Therapie(neben)wirkungen in einem angemessenen Verhältnis zum Therapienutzen?
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Albertsen PC, Fryback DG et al. (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156: 127–132
Ausili-Cefaro G, Olmi P (2001) The role of radiotherapy in the management of elderly cancer patients in light of the GROG experience. Critl Rev Oncol Hematol 39: 313–317
Barry MJ, Albertsen PC, Bagshaw MA et al. (2001) Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 91: 2302–2314
Charlson ME, Pompei P, Ales KL et al. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383
Clark PE, Stein JP, Groshen SG et al. (2005) Radical cystectomy in the elderly: comparison of survival between younger and older patients. Cancer 103: 546–552
Coebergh JW, Janssen-Heijnen ML et al. (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 1993–1996. J Clin Epidemiol 52: 1131–1136
Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36: 453–471
Folstein MF, Folstein SE, Mc Mugh PR (1975) „Mini-Mental State“: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198
Froehner M, Koch FR, Litz R et al. (2003) Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology 62: 698–701
Froehner M, Koch R, Litz R et al. (2004) Which conditions contributing to the Charlson score predict survival after radical prostatectomy? J Urol 171: 697–699
Greenfield S, Blanco DM et al. (1987) Patterns of care related to age of breast cancer patients. J Am Med Assoc 257: 2766–2770
Guigoz Y, Vellas B and Garry PJ (1994) Mini Nutritional Assessment: A practical assessment tool for grading the nutritional state of elderly patients. Facts and research in gerontology. Supplement 2: 15–59
Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M, Bullock R (2004) DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriat Psychiat 19: 136–43
Kaplan MH, Feinstein AR (1974) The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27: 387–404
Kattan MW, Cowen ME et al. (1997) A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 12: 299–305
Lawton MP, Brody EM (1988) Instrumantal Activities of Daily Living (IADL) Scale-Self-rated version. Psychopharmacol Bull. 24: 789–92
Mahoney FI, Barthel DW (1965) Functional evaluation. The Barthel Index. Md State Med J 14/2: 61–65
Newschaffer CJ, Bush TL et al. (1996) Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol Biol Sci Med Sci 53: 372–378
Podsiadlo D, Richardson S (1991) The timed „Up and Go“: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39: 142–148
Sheikh JI, Yesavage JA (1986) Geriatric Depression Scale (GDS)-Recent evidence and development of a shorter version. Clin Gerontol 5: 165–73
Thomas DM, Riddle PR (1982) Morbidity and mortality in 100 consecutive radical cystectomies. Br J Urol 54: 716–719
Watson IJ, Arfken CL, Birge SJ (1993) Clock completion: An objective Screening test for dementia. J Am Geriat Soc 41: 1235–1240
Welch HG, Albertsen PC et al. (1996) Assessing competing risks in treating the elderly. Hosp Pract (Off Edn) 31: 155–156, 158-159,162
Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT (2003) Pharmacology of anticancer drugs in the elderly population. Clinical Pharmacokinetics 42: 1213–42
Wolters U, Wolf T, Stutzer H (1996) ASA classifications and perioperative variables as predictors of postoperative outcome. Br J Anesth 77: 217–222
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Friedrich, C., Krege, S., Wedding, U., Pientka, L. (2007). Uroonkologie beim älteren Patienten. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-33848-2_13
Download citation
DOI: https://doi.org/10.1007/978-3-540-33848-2_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-33847-5
Online ISBN: 978-3-540-33848-2
eBook Packages: Medicine (German Language)